ID   ARK
AC   CVCL_A760
SY   Ark; ark; ARK-B
DR   BTO; BTO_0003930
DR   cancercelllines; CVCL_A760
DR   Cosmic; 720774
DR   Cosmic; 760398
DR   Cosmic; 2302413
DR   Cosmic; 2367270
DR   Wikidata; Q54750449
RX   DOI=10.1007/0-306-46877-8_4;
RX   PubMed=8051085;
RX   PubMed=8427968;
RX   PubMed=8943038;
RX   PubMed=10936422;
RX   PubMed=11001907;
RX   PubMed=11157491;
RX   PubMed=11167840;
RX   PubMed=14555701;
RX   PubMed=15381930;
CC   Sequence variation: Mutation; HGNC; HGNC:7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (PubMed=11157491).
CC   Derived from site: In situ; Bone marrow; UBERON=UBERON_0002371.
CC   Cell type: B-cell; CL=CL_0000236.
DI   NCIt; C3242; Plasma cell myeloma
DI   ORDO; Orphanet_29073; Multiple myeloma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 19-12-24; Version: 18
//
RX   DOI=10.1007/0-306-46877-8_4;
RA   Jernberg-Wiklund H., Nilsson K.;
RT   "Multiple myeloma cell lines.";
RL   (In book chapter) Human cell culture. Vol. 3. Cancer cell lines part 3; Masters J.R.W., Palsson B.O. (eds.); pp.81-155; Kluwer Academic Publishers; New York; USA (2000).
//
RX   PubMed=8051085; DOI=10.1016/S0021-9258(17)32120-8;
RA   Liebersbach B.F., Sanderson R.D.;
RT   "Expression of syndecan-1 inhibits cell invasion into type I
RT   collagen.";
RL   J. Biol. Chem. 269:20013-20019(1994).
//
RX   PubMed=8427968; DOI=10.1182/blood.V81.3.767.767;
RA   Ridley R.C., Xiao H.-Q., Hata H., Woodliff J., Epstein J.,
RA   Sanderson R.D.;
RT   "Expression of syndecan regulates human myeloma plasma cell adhesion
RT   to type I collagen.";
RL   Blood 81:767-774(1993).
//
RX   PubMed=8943038; DOI=10.1073/pnas.93.24.13931; PMCID=PMC19472;
RA   Bergsagel P.L., Chesi M., Nardini E., Brents L.A., Kirby S.L.,
RA   Kuehl W.M.;
RT   "Promiscuous translocations into immunoglobulin heavy chain switch
RT   regions in multiple myeloma.";
RL   Proc. Natl. Acad. Sci. U.S.A. 93:13931-13936(1996).
//
RX   PubMed=10936422; DOI=10.1016/S0145-2126(99)00195-2;
RA   Drexler H.G., Matsuo Y.;
RT   "Malignant hematopoietic cell lines: in vitro models for the study of
RT   multiple myeloma and plasma cell leukemia.";
RL   Leuk. Res. 24:681-703(2000).
//
RX   PubMed=11001907; DOI=10.1182/blood.V96.7.2528;
RA   Borset M., Hjertner O., Yaccoby S., Epstein J., Sanderson R.D.;
RT   "Syndecan-1 is targeted to the uropods of polarized myeloma cells
RT   where it promotes adhesion and sequesters heparin-binding proteins.";
RL   Blood 96:2528-2536(2000).
//
RX   PubMed=11157491; DOI=10.1182/blood.V97.3.729;
RA   Chesi M., Brents L.A., Ely S.A., Bais C., Robbiani D.F., Mesri E.A.,
RA   Kuehl W.M., Bergsagel P.L.;
RT   "Activated fibroblast growth factor receptor 3 is an oncogene that
RT   contributes to tumor progression in multiple myeloma.";
RL   Blood 97:729-736(2001).
//
RX   PubMed=11167840; DOI=10.1046/j.1365-2141.2001.02531.x;
RA   Chiriva-Internati M., Du J.-H., Cannon M., Barlogie B., Yi Q.;
RT   "Myeloma-reactive allospecific cytotoxic T lymphocytes lyse target
RT   cells via the granule exocytosis pathway.";
RL   Br. J. Haematol. 112:410-420(2001).
//
RX   PubMed=14555701;
RA   Shammas M.A., Shmookler Reis R.J., Akiyama M., Koley H., Chauhan D.,
RA   Hideshima T., Goyal R.K., Hurley L.H., Anderson K.C., Munshi N.C.;
RT   "Telomerase inhibition and cell growth arrest by G-quadruplex
RT   interactive agent in multiple myeloma.";
RL   Mol. Cancer Ther. 2:825-833(2003).
//
RX   PubMed=15381930; DOI=10.1038/sj.bjc.6602160; PMCID=PMC2409933;
RA   Wang Z.-Q., Zhang Y., Ramsahoye B., Bowen D.J., Lim S.H.;
RT   "Sp17 gene expression in myeloma cells is regulated by promoter
RT   methylation.";
RL   Br. J. Cancer 91:1597-1603(2004).
//